CD5+ SLVL

From: Randy Gascoyne (rgascoyn@bccancer.bc.ca)
Date: Wed Aug 02 2000 - 16:37:11 EST


Hi Gang...I never use this forum, but can't resist this one.
I also agree with Dan Arber. The response he recieved about the 1994 Blood
paper is misleading. At that time, the so-called SLVL collection in London
had about 30% cases with t(11;14). We all know what these are!! Peter
Isaacson told all of us at a meeting many years ago, related to his Blood
paper on the histopathology of SLVL, that virtually all of these cases were
MCLs. Thus, CD5 positivity in SLVL is likely impossible to interpret from
the published literature. However, he also claimed to see CD5 infrequently
and discussed in that paper the distinctions between PB flow and
frozen-section Ipox. He also made note of variable phenotypes as cells move
from one compartment to another!
My best guess is that SLVL/HCL-variant etc is likely to be one of several
choices. Most are likely MZLs of different types. We now know about CD5+
MALT lymphomas with a tendency to involve BM and likely blood as well (AJCP
paper with Nancy Harris). Remember that Bill Pugh presented a small number
of cases at US&CAP many years ago (before the Harris paper). If one looks at
the cytogenetic data from the literature, it gets even more interesting. I
came across several papers about HCL, HCL-variant etc, some of which had
isolated del 7q31-32. This cytogenetic finding is almost certainly tightly
connected to primary splenic marginal zone. I would guess that classical
cytogenetics and/or other PCR-based approaches (how about taking such cases
and CD5-negative ones and doing RT-PCR for the AP12-MLT rearrangement),
together with gene expression data will likely help to clarify much of the
confusion in the literature. Otherwise, this will continue to be a problem
area because of the vagaries of PB morphology/interpretation and the
reliance of so-called "signature" phenotypes. Moreover, PB morphology cannot
be equated in anyway with histology in most of these cases. Are people
surprized to know that MCL (Bcl-1 proven) are CD5-negative in 3% of cases!!

		Randy Gascoyne

Randy D. Gascoyne
Department of Pathology
British Columbia Cancer Agency
600 W 10th Avenue
Vancouver, BC
Canada V5Z 4E6
Phone: (604) 877-6098, local # 2097
Fax: (604) 877-6178
E-mail: rgascoyn@bccancer.bc.ca



This archive was generated by hypermail 2b29 : Sat Mar 10 2001 - 19:31:28 EST